November 11-13, 2023 | Philadelphia, PA
Learn about Amgen's pipeline clinical trials in ASCVD and obesity
Effect of Evolocumab in patients at high CV risk without prior MI or Stroke. This is an investigational study.†
*Safety and efficacy have not been established.
†Evolocumab is not indicated for this intended use.
ASCVD: Atherosclerotic cardiovascular disease, CV: Cardiovascular, MI: Myocardial Infarction, RWE: Real World Evidence, T2DM: Type 2 Diabetes Mellitus